Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer

Abstract

Our analysis revealed that the TME score was an indicator of patients' response to immune checkpoint modulators and an effective prognostic biomarker. TME scoring improves current immunotherapy on luminal B breast cancer.